Matches in SemOpenAlex for { <https://semopenalex.org/work/W2900695753> ?p ?o ?g. }
Showing items 1 to 90 of
90
with 100 items per page.
- W2900695753 endingPage "193" @default.
- W2900695753 startingPage "193" @default.
- W2900695753 abstract "193 Despite the improvement of conventional antitumor therapies including chemotherapy, radiotherapy, and surgical resection, the prognosis of lung cancer patients remains extremely poor. Therefore, to improve patient survival, novel therapies need to be developed. Prostate stem cell antigen (PSCA) is a glycosylphosphatidylinositol-anchored cell-surface protein belonging to the Ly-6/Thy-1 family of cell surface antigen. It has been originally identified to be an overexpressed gene in human prostate cancer. Its overexpression has been correlated with disease progression. Furthermore, recent studies have reported the expression of PSCA in a few other malignancies including pancreatic cancer. However, the clinical importance and function of PSCA expression in human malignancies was largely unknown. In this study, we tried to reveal the significance and therapeutic potential of PSCA in human lung cancer. We performed immunohistochemical analysis of PSCA expression using anti-human PSCA mAb in 55 lung cancer patients who underwent curative resection from Jury 2002 through December 2003. PSCA was stained mainly in the cytoplasm of tumor cells, and its expression was detected in 44 of 55 (80.0%). Patients without PSCA expression had a tendency to be at earlier stage than the positive patients, although differences did not reach statistical significance. Pathological stage classification was as follows: PSCA-positive; 25 in Stage I (56.8%), 9 in Stage II (16.4%), 9 in Stage III (16.4%), and 1 in Stage IV (2.2%), PSCA-negative; 9 in Stage I (81.8%), 1 in Stage II (9.1%), 1 in Stage III (9.1%), 0 in Stage IV (0%). Tumor size was 35.5±18.1 mm for PSCA positive and 31.9±11.8 for negative, respectively (mean ± standard deviation). While 16 out of 44 patients with positive PSCA expression had lymph node metastasis (36.4%: 28 in N0, 9 in N1, and 7 in N2), only one out of 11 patients with negative PSCA had lymph node metastasis (9.1%: 10 in N0 and 1 in N1). Furthermore, PSCA negative patients had a tendency to have a better prognosis than the positive patients (P = 0.072, the 3-year disease-free survival rate; 90.0% v.s. 62.3%). In conclusion, we demonstrate for the first time that PSCA was highly expressed in human lung cancer. Also we suggest that PSCA may be functionally critical for human lung cancer. Thus PSCA may be a novel therapeutic target for this fatal disease." @default.
- W2900695753 created "2018-11-29" @default.
- W2900695753 creator A5014822163 @default.
- W2900695753 creator A5018521703 @default.
- W2900695753 creator A5032886131 @default.
- W2900695753 creator A5035027513 @default.
- W2900695753 creator A5037685525 @default.
- W2900695753 creator A5043562194 @default.
- W2900695753 creator A5044881516 @default.
- W2900695753 creator A5073463502 @default.
- W2900695753 creator A5081112815 @default.
- W2900695753 creator A5087154078 @default.
- W2900695753 date "2007-05-01" @default.
- W2900695753 modified "2023-09-22" @default.
- W2900695753 title "Significance of prostate stem cell antigen expression in human lung cancer" @default.
- W2900695753 hasPublicationYear "2007" @default.
- W2900695753 type Work @default.
- W2900695753 sameAs 2900695753 @default.
- W2900695753 citedByCount "0" @default.
- W2900695753 crossrefType "journal-article" @default.
- W2900695753 hasAuthorship W2900695753A5014822163 @default.
- W2900695753 hasAuthorship W2900695753A5018521703 @default.
- W2900695753 hasAuthorship W2900695753A5032886131 @default.
- W2900695753 hasAuthorship W2900695753A5035027513 @default.
- W2900695753 hasAuthorship W2900695753A5037685525 @default.
- W2900695753 hasAuthorship W2900695753A5043562194 @default.
- W2900695753 hasAuthorship W2900695753A5044881516 @default.
- W2900695753 hasAuthorship W2900695753A5073463502 @default.
- W2900695753 hasAuthorship W2900695753A5081112815 @default.
- W2900695753 hasAuthorship W2900695753A5087154078 @default.
- W2900695753 hasConcept C121608353 @default.
- W2900695753 hasConcept C126322002 @default.
- W2900695753 hasConcept C142724271 @default.
- W2900695753 hasConcept C143998085 @default.
- W2900695753 hasConcept C146357865 @default.
- W2900695753 hasConcept C147483822 @default.
- W2900695753 hasConcept C151730666 @default.
- W2900695753 hasConcept C203014093 @default.
- W2900695753 hasConcept C204232928 @default.
- W2900695753 hasConcept C2776256026 @default.
- W2900695753 hasConcept C2780192828 @default.
- W2900695753 hasConcept C502942594 @default.
- W2900695753 hasConcept C509974204 @default.
- W2900695753 hasConcept C71924100 @default.
- W2900695753 hasConcept C86803240 @default.
- W2900695753 hasConceptScore W2900695753C121608353 @default.
- W2900695753 hasConceptScore W2900695753C126322002 @default.
- W2900695753 hasConceptScore W2900695753C142724271 @default.
- W2900695753 hasConceptScore W2900695753C143998085 @default.
- W2900695753 hasConceptScore W2900695753C146357865 @default.
- W2900695753 hasConceptScore W2900695753C147483822 @default.
- W2900695753 hasConceptScore W2900695753C151730666 @default.
- W2900695753 hasConceptScore W2900695753C203014093 @default.
- W2900695753 hasConceptScore W2900695753C204232928 @default.
- W2900695753 hasConceptScore W2900695753C2776256026 @default.
- W2900695753 hasConceptScore W2900695753C2780192828 @default.
- W2900695753 hasConceptScore W2900695753C502942594 @default.
- W2900695753 hasConceptScore W2900695753C509974204 @default.
- W2900695753 hasConceptScore W2900695753C71924100 @default.
- W2900695753 hasConceptScore W2900695753C86803240 @default.
- W2900695753 hasLocation W29006957531 @default.
- W2900695753 hasOpenAccess W2900695753 @default.
- W2900695753 hasPrimaryLocation W29006957531 @default.
- W2900695753 hasRelatedWork W1786251417 @default.
- W2900695753 hasRelatedWork W1920368998 @default.
- W2900695753 hasRelatedWork W1991748394 @default.
- W2900695753 hasRelatedWork W2018847835 @default.
- W2900695753 hasRelatedWork W2024127842 @default.
- W2900695753 hasRelatedWork W2061046382 @default.
- W2900695753 hasRelatedWork W2142940604 @default.
- W2900695753 hasRelatedWork W2157943220 @default.
- W2900695753 hasRelatedWork W2284408622 @default.
- W2900695753 hasRelatedWork W2439368546 @default.
- W2900695753 hasRelatedWork W2545269156 @default.
- W2900695753 hasRelatedWork W2654384024 @default.
- W2900695753 hasRelatedWork W2805582315 @default.
- W2900695753 hasRelatedWork W2875388802 @default.
- W2900695753 hasRelatedWork W2887584137 @default.
- W2900695753 hasRelatedWork W2991998616 @default.
- W2900695753 hasRelatedWork W3095623462 @default.
- W2900695753 hasRelatedWork W3121250799 @default.
- W2900695753 hasRelatedWork W3176922803 @default.
- W2900695753 hasRelatedWork W2346445050 @default.
- W2900695753 hasVolume "67" @default.
- W2900695753 isParatext "false" @default.
- W2900695753 isRetracted "false" @default.
- W2900695753 magId "2900695753" @default.
- W2900695753 workType "article" @default.